Pharmaleads' Lead Candidate For Pain, PL37, Enters Phase I Pharmaleads has obtained from the French
Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain.
Source: www.medicalnewstoday.comCircassia Initiates Further Phase II Clinical Study Of Toleromune(R) Anti Allergy Technology Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization.
Source: www.medicalnewstoday.com
# posted by Network @ 1:00 PM
